117 related articles for article (PubMed ID: 12451286)
41. Effects of quercetin on the pharmacokinetics of Etoposide after oral or intravenous administration of etoposide in rats.
Li X; Choi JS
Anticancer Res; 2009 Apr; 29(4):1411-5. PubMed ID: 19414395
[TBL] [Abstract][Full Text] [Related]
42. [Pharmacokinetics of etoposide short-term infusions within the scope of the GPOH therapy protocol].
Boos J; Real E; Schulze-Westhoff P; Pröbsting B; Wolff J; Jürgens H
Klin Padiatr; 1993; 205(4):288-94. PubMed ID: 8377449
[TBL] [Abstract][Full Text] [Related]
43. Development of a population pharmacokinetic model for carbamazepine based on sparse therapeutic monitoring data from pediatric patients with epilepsy.
Carlsson KC; Hoem NO; Glauser T; Vinks AA
Clin Ther; 2005 May; 27(5):618-26. PubMed ID: 15978311
[TBL] [Abstract][Full Text] [Related]
44. Optimization of oral etoposide dosage in elderly patients with non-Hodgkin's lymphoma using the fraction of dose absorbed measured for each patient.
el-Yazigi A; Ezzat A; Berry J; Raines DA; Yusuf A; al-Rawithi S; Legayada ES
J Clin Pharmacol; 2000 Feb; 40(2):153-60. PubMed ID: 10664921
[TBL] [Abstract][Full Text] [Related]
45. Effect of cyclosporine A on the tissue distribution and pharmacokinetics of etoposide.
Cárcel-Trullols J; Torres-Molina F; Araico A; Saadeddin A; Peris JE
Cancer Chemother Pharmacol; 2004 Aug; 54(2):153-60. PubMed ID: 15114410
[TBL] [Abstract][Full Text] [Related]
46. Phase I and pharmacologic study of 7- and 21-day continuous etoposide infusion in patients with advanced cancer.
Robert F; Chen S; Miller AA; Lee BC; Molthrop DC; Wheeler RH
Cancer Chemother Pharmacol; 1996; 38(5):459-65. PubMed ID: 8765440
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetic analysis of etoposide distribution after administration directly into the fourth ventricle in a piglet model.
Sandberg DI; Crandall KM; Koru-Sengul T; Padgett KR; Landrum J; Babino D; Petito CK; Solano J; Gonzalez-Brito M; Kuluz JW
J Neurooncol; 2010 Mar; 97(1):25-32. PubMed ID: 19688296
[TBL] [Abstract][Full Text] [Related]
48. A lyophilized etoposide submicron emulsion with a high drug loading for intravenous injection: preparation, evaluation, and pharmacokinetics in rats.
Chen H; Shi S; Zhao M; Zhang L; He H; Tang X
Drug Dev Ind Pharm; 2010 Dec; 36(12):1444-53. PubMed ID: 21050136
[TBL] [Abstract][Full Text] [Related]
49. Plasma pharmacokinetics of etoposide (VP-16) after i.v. administration to children.
Eksborg S; Söderhäll S; Frostvik-Stolt M; Lindberg A; Liliemark E
Anticancer Drugs; 2000 Apr; 11(4):237-41. PubMed ID: 10898537
[TBL] [Abstract][Full Text] [Related]
50. Validation of a limited sampling model to determine etoposide area under the curve.
Lum BL; Lane KJ; Synold TW; Goram A; Charnick SB; Sikic BI
Pharmacotherapy; 1997; 17(5):887-90. PubMed ID: 9324178
[TBL] [Abstract][Full Text] [Related]
51. Excel-Based Tool for Pharmacokinetically Guided Dose Adjustment of Paclitaxel.
Kraff S; Lindauer A; Joerger M; Salamone SJ; Jaehde U
Ther Drug Monit; 2015 Dec; 37(6):725-32. PubMed ID: 25774704
[TBL] [Abstract][Full Text] [Related]
52. Relation between unbound plasma concentrations and toxicity in a prolonged oral etoposide schedule.
Perdaems N; Bachaud JM; Rouzaud P; Murris-Espin M; Hermant C; Mihura J; Lochon I; Houin G; Canal P; Chatelut E
Eur J Clin Pharmacol; 1998; 54(9-10):677-83. PubMed ID: 9923567
[TBL] [Abstract][Full Text] [Related]
53. A tool for neutrophil guided dose adaptation in chemotherapy.
Wallin JE; Friberg LE; Karlsson MO
Comput Methods Programs Biomed; 2009 Mar; 93(3):283-91. PubMed ID: 19084287
[TBL] [Abstract][Full Text] [Related]
54. Low dose--high dose: what is the right dose? Pharmacokinetic modeling of etoposide.
Würthwein G; Boos J
Cancer Chemother Pharmacol; 2002 Apr; 49(4):303-8. PubMed ID: 11914910
[TBL] [Abstract][Full Text] [Related]
55. A limited sampling strategy for estimating individual pharmacokinetic parameters of coagulation factor VIII in patients with hemophilia A.
Bolon-Larger M; Chamouard V; Bressolle F; Boulieu R
Ther Drug Monit; 2007 Feb; 29(1):20-6. PubMed ID: 17304146
[TBL] [Abstract][Full Text] [Related]
56. Randomized comparison of etoposide pharmacokinetics after oral etoposide phosphate and oral etoposide.
de Jong RS; Mulder NH; Uges DR; Kaul S; Winograd B; Sleijfer DTh ; Groen HJ; Willemse PH; van der Graaf WT; de Vries EG
Br J Cancer; 1997; 75(11):1660-6. PubMed ID: 9184183
[TBL] [Abstract][Full Text] [Related]
57. Drug monitoring of etoposide (VP16-213). Correlation of pharmacokinetic parameters to clinical and biochemical data from patients receiving etoposide.
Pflüger KH; Schmidt L; Merkel M; Jungclas H; Havemann K
Cancer Chemother Pharmacol; 1987; 20(1):59-66. PubMed ID: 3621455
[TBL] [Abstract][Full Text] [Related]
58. Clinical and pharmacokinetic study of fractionated doses of oral etoposide in pediatric patients with advanced malignancies.
Gregianin LJ; Brunetto AL; Di Leone L; Costa TD; Santos PP; Schwartsmann G
Med Sci Monit; 2002 Sep; 8(9):PI70-7. PubMed ID: 12218955
[TBL] [Abstract][Full Text] [Related]
59. Chemotherapy administration directly into the fourth ventricle in a new piglet model. Laboratory Investigation.
Sandberg DI; Crandall KM; Petito CK; Padgett KR; Landrum J; Babino D; He D; Solano J; Gonzalez-Brito M; Kuluz JW
J Neurosurg Pediatr; 2008 May; 1(5):373-80. PubMed ID: 18447671
[TBL] [Abstract][Full Text] [Related]
60. Etoposide encapsulated in positively charged liposomes: pharmacokinetic studies in mice and formulation stability studies.
Sengupta S; Tyagi P; Velpandian T; Gupta YK; Gupta SK
Pharmacol Res; 2000 Nov; 42(5):459-64. PubMed ID: 11023708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
